LifeWatch ditches public offering bid:
This article was originally published in Clinica
Executive Summary
Cardiac monitoring company LifeWatch has cancelled its proposed IPO of around $86.3m worth of common stock. In a registration statement to the US Securities and Exchange Commission, the Rosemont, Illinois-based firm said that its board of directors had decided that "pursuing the initial public offering at this time is not in the best interests of the company". The IPO, which was originally filed in December 2006, was expected to provide funding to repay outstanding debt to LifeWatch's parent company, Swiss healthcare technology and solutions provider CardGuard. LifeWatch was also planning to use the proceeds to purchase, launch and market CardGuard's LifeStar ACT cardiac monitoring device and to support the relocation of its production facilities to a new site.
You may also be interested in...
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.